Search research articles
Contact Us
Filters
Showing results (11-20 of 46) with videos related to
Page
of 5
Sort By:
Children (Basel, Switzerland)
|
July 16, 2016
A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical Trials
Klaus Rose, Hans Kummer
Pharmaceutical Statistics
|
June 7, 2014
Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm
Klaus Rose, Stephen Senn
World Journal of Clinical Pediatrics
|
June 10, 2025
Disorders of gut-brain interaction are a new challenge of our increasingly complex society, with worldwide repercussions
Earl B Ettienne, Klaus Rose
Clinical Therapeutics
|
February 5, 2017
Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?
Klaus Rose, Philip D Walson
Current Therapeutic Research, Clinical and Experimental
|
August 8, 2019
Are Regulatory Age Limits in Pediatric Melanoma Justified?
Klaus Rose, Philip D Walson
World Journal of Clinical Pediatrics
|
June 10, 2025
African minors' health challenges are comparable to those in the rest of the world
Earl B Ettienne, Klaus Rose
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|
October 27, 2015
Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health
Klaus Rose, Matthias Volkmar Kopp
Handbook of Experimental Pharmacology
|
September 2, 2011
Development of paediatric medicines: concepts and principles
Klaus Rose, Oscar Della Pasqua
Paediatric Drugs
|
September 11, 2017
Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?
Klaus Rose, Philip D Walson
Children (Basel, Switzerland)
|
July 16, 2016
Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency
Klaus Rose, Michael G Spigarelli
Page
of 5
Search research articles
Search
Showing results (11-20 of 46) with videos related to
Sort By:
Page
of 5
Children (Basel, Switzerland)
|
July 16, 2016
A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical Trials
Klaus Rose, Hans Kummer
Pharmaceutical Statistics
|
June 7, 2014
Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm
Klaus Rose, Stephen Senn
World Journal of Clinical Pediatrics
|
June 10, 2025
Disorders of gut-brain interaction are a new challenge of our increasingly complex society, with worldwide repercussions
Earl B Ettienne, Klaus Rose
Clinical Therapeutics
|
February 5, 2017
Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?
Klaus Rose, Philip D Walson
Current Therapeutic Research, Clinical and Experimental
|
August 8, 2019
Are Regulatory Age Limits in Pediatric Melanoma Justified?
Klaus Rose, Philip D Walson
World Journal of Clinical Pediatrics
|
June 10, 2025
African minors' health challenges are comparable to those in the rest of the world
Earl B Ettienne, Klaus Rose
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|
October 27, 2015
Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health
Klaus Rose, Matthias Volkmar Kopp
Handbook of Experimental Pharmacology
|
September 2, 2011
Development of paediatric medicines: concepts and principles
Klaus Rose, Oscar Della Pasqua
Paediatric Drugs
|
September 11, 2017
Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?
Klaus Rose, Philip D Walson
Children (Basel, Switzerland)
|
July 16, 2016
Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency
Klaus Rose, Michael G Spigarelli
Page
of 5